Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis

Table 4 Comparative analysis of AITL patients who received prior auto-HCT vs no prior auto-HCT

Outcomes	No prior auto-HCT (N = 151)		Prior auto-HCT (N = 98)		p value
Outcomes	N	Prob (95% CI)	N	Prob (95% CI)	p value
NRM	151		98		0.25
1-year		17 (11–23)%		22 (14–30)%	0.33
2-year		21 (15–28)%		31 (22–41)%	0.08
3-year		22 (16–29)%		33 (23–43)%	0.07
4-year		26 (19–34)%		36 (26–47)%	0.11
Progression/relapse	151		98		0.69
1-year		16 (11–22)%		15 (8–22)%	0.77
2-year		22 (15–29)%		16 (9–24)%	0.23
3-year		23 (16–30)%		17 (10–25)%	0.28
4-year		24 (17–31)%		17 (10–25)%	0.21
PFS	151		98		0.45
1-year		68 (60–75)%		64 (54–73)%	0.56
2-year		57 (49–65)%		53 (43–63)%	0.53
3-year		55 (47–64)%		50 (40–61)%	0.43
4-year		50 (42–59)%		47 (36–57)%	0.60
Overall survival	151		98		0.81
1-year		73 (65–80)%		74 (65–82)%	0.81
2-year		65 (57–72)%		59 (49–69)%	0.43
3-year		61 (53–69)%		58 (47–68)%	0.63
4-year		57 (49–65)%		54 (44–65)%	0.70

Prob probability, CI confidence interval, N number, NRM non-relapse mortality, PFS progression-free survival, HCT hematopoietic cell transplantation

ISSN: 1756-8722